These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34689051)

  • 1. Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
    Ong HT; Teo YH; Teo YN; Syn NL; Wee CF; Leong S; Yip ASY; See RM; Ting AZH; Chia AZ; Cheong AJY; Tan BY; Ho JS; Yeo LL; Leow AS; Yeo TC; Wong RC; Chai P; Kojodjojo P; Sia CH
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106159. PubMed ID: 34689051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
    Zheng RJ; Wang Y; Tang JN; Duan JY; Yuan MY; Zhang JY
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):e145-e152. PubMed ID: 34813574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
    Xu B; Kang B; Zhou J
    Clin Res Cardiol; 2024 Jun; 113(6):910-923. PubMed ID: 38353684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis.
    Zhang HD; Ding L; Mi LJ; Zhang AK; Zhang K; Jiang ZH; Yu FY; Yan XX; Shen YJ; Tang M
    Eur J Prev Cardiol; 2024 May; 31(7):770-779. PubMed ID: 37966828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
    Zhou Z; Jardine MJ; Li Q; Neuen BL; Cannon CP; de Zeeuw D; Edwards R; Levin A; Mahaffey KW; Perkovic V; Neal B; Lindley RI;
    Stroke; 2021 May; 52(5):1545-1556. PubMed ID: 33874750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials.
    Cheong AJY; Teo YN; Teo YH; Syn NL; Ong HT; Ting AZH; Chia AZQ; Chong EY; Chan MY; Lee CH; Lim AYL; Kong WKF; Wong RCC; Chai P; Sia CH
    Obesity (Silver Spring); 2022 Jan; 30(1):117-128. PubMed ID: 34932882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
    Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
    Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.
    Aziri B; Begic E; Jankovic S; Mladenovic Z; Stanetic B; Kovacevic-Preradovic T; Iglica A; Mujakovic A
    ESC Heart Fail; 2023 Jun; 10(3):1499-1530. PubMed ID: 36967133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF
    J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials.
    Teo YH; Chia AZQ; Teo YN; Chong EY; Syn NL; Cheong JYA; Ong HT; Wee CF; Ting AZH; Tan JTA; Li TYW; Kong WKF; Lee CH; Chan MY; Wong RCC; Yeo TC; Chai P; Sia CH
    J Hypertens; 2022 Dec; 40(12):2353-2372. PubMed ID: 36018229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Stroke and Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Fatima K; Suri A; Rija A; Kalim S; Javaid S; Arif Z; Abedin MFE; Raza Y; Kalim N; Azam F; Musani S
    Curr Probl Cardiol; 2023 Apr; 48(4):101582. PubMed ID: 36584726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
    Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure.
    Shrestha DB; Budhathoki P; Sedhai YR; Karki P; Gurung S; Raut S; Damonte JI; Del Buono MG; Mojadidi MK; Elgendy IY; Patel T; Patel NK
    J Cardiovasc Pharmacol; 2021 Oct; 78(4):501-514. PubMed ID: 34269700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis.
    Guo M; Ding J; Li J; Wang J; Zhang T; Liu C; Huang W; Long Y; Gao C; Xu Y
    Diabetes Obes Metab; 2018 Aug; 20(8):1977-1982. PubMed ID: 29573118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.